Expert Review of Cardiovascular Therapy
-
Publication Venue For
- Role of proprotein convertase subtilisin/kexin type 9 inhibitors in patients with coronary artery disease undergoing percutaneous coronary intervention.. 16:419-429. 2018
- Current controversies in the use of aspirin and ticagrelor for the treatment of thrombotic events.. 14:1361-1370. 2016
- Extended-release acetylsalicylic acid for secondary prevention of stroke and cardiovascular events.. 14:779-791. 2016
- Vorapaxar in the secondary prevention of atherothrombosis.. 13:1293-1305. 2015
- Bucindolol hydrochloride in atrial fibrillation and concomitant heart failure.. 13:627-636. 2015
- Combination decongestion therapy in hospitalized heart failure: loop diuretics, mineralocorticoid receptor antagonists and vasopressin antagonists.. 13:799-809. 2015
- The potential role of natriuretic peptides and other biomarkers in heart failure diagnosis, prognosis and management.. 13:1017-1030. 2015
- Importance of measurement of platelet reactivity to ADP in patients with coronary artery disease: an historical account.. 11:1547-1556. 2013
- Progression of radial approach to PCI in the USA: from niche procedure to default approach.. 11:1271-1273. 2013
- A review of apixaban for stroke prevention in atrial fibrillation: insights from ARISTOTLE.. 11:1105-1114. 2013
- Potential role of oral anticoagulants in the treatment of patients with coronary artery disease: focus on dabigatran.. 11:1259-1267. 2013
- Is bleeding a necessary evil? The inherent risk of antithrombotic pharmacotherapy used for stroke prevention in atrial fibrillation.. 11:1029-1049. 2013
- The next 10 years in personalized medicine in cardiology.. 11:933-935. 2013
- Influence of genetic polymorphisms on platelet function, response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease.. 11:447-462. 2013
- Role of genotype-based personalized antiplatelet therapy in the era of potent P2Y₁₂ receptor inhibitors.. 10:1011-1022. 2012
- Gastroesophageal reflux and atrial fibrillation: is there any correlation?. 10:317-322. 2012
- Should stress management be incorporated into cardiac rehabilitation?. 10:135-137. 2012
- Cell therapy for heart failure: the need for a new therapeutic strategy.. 8:1107-1126. 2010
- Efficacy and safety of nesiritide in patients with acute decompensated heart failure.. 8:159-169. 2010
- Clevidipine in the treatment of perioperative hypertension: assessing safety events in the ECLIPSE trials.. 7:465-472. 2009
- Management of Hypertension in Heart failure. Revisiting the Guidelines. 4:423-433. 2009
- Metabolic efficiency with ranolazine for less ischemia in non-ST elevation acute coronary syndromes (MERLIN TIMI-36) study.. 6:9-16. 2008
- New insights and therapeutics for immune-mediated thrombocytopenia.. 6:71-84. 2008
- Present and evolving role of eptifibatide in the treatment of acute coronary syndromes.. 5:401-412. 2007
- Cardiovascular MRI: its current and future use in clinical practice.. 5:307-321. 2007
- The use of TP10, soluble complement receptor 1, in cardiopulmonary bypass.. 4:649-654. 2006
- Role of beta-adrenergic receptor signaling and desensitization in heart failure: new concepts and prospects for treatment.. 4:417-432. 2006
- Angiogenic therapy for coronary artery and peripheral arterial disease.. 3:521-535. 2005
- N-terminal proBNP: a novel biomarker for the diagnosis, risk stratification and management of congestive heart failure.. 3:487-496. 2005